NCP26

Overview

NCP26 is an ATP-competitive ProRS inhibitor (with a K D of 271 nM in the absence of proline, and a K D of 0.35 nM in the presence of 100 μM proline). NCP26 activates AAR , induces G0/G1 phase arrest, Apoptosis , Caspase cleavage, and PARP cleavage. NCP26 downregulates MYC , TCF3 , and CCND1 . NCP26 inhibits the growth of multiple myeloma cells. NCP26 can be used for the research of multiple myeloma.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Multiple Myeloma | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > c-Myc | Products > Signaling Pathways > Aminoacyl-tRNA Synthetase | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Caspase | Products > Signaling Pathways > PARP

Product Information

• Catalog No.: HY-183004
• CAS No.: 2396683-89-7
• Molecular Formula: C20H23N5O2
• Molecular Weight: 365.44
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source